🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Yu Fujiwara

Tokyo Medical and Dental University

ORCID: 0000-0003-1406-2352

Also affiliated with Roswell Park Comprehensive Cancer Center, Tokyo Fuji University

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study”.

Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study

Journal of Thoracic Oncology(2024)10.1016/j.jtho.2024.01.012
N/A
0.571DataRank · unranked
44 citations

So Yeon Kim, Jacqueline V. Aredo, Jamie Feng, Frances A. Shepherd, Chao Xu +52 more

High indoleamine 2,3-dioxygenase transcript levels predict better outcome after front-line cancer immunotherapy

iScience(2024)10.1016/j.isci.2024.109632
N/A
0.360DataRank · unranked
10 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary Nesline +6 more

Pan-cancer B- and T-cell transcriptome analysis of CXCL13 as a predictive marker for immune checkpoint inhibitor response.

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.2626
N/A
0.104DataRank · unranked
1 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary Nesline +5 more

Pan-cancer analysis of IDO1 transcriptome expression and its impact on outcome in patients treated with immune checkpoint inhibitors.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.2614
N/A
0DataRank · unranked
0 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary Nesline +6 more

Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards

Surgical Oncology Clinics of North America(2023)10.1016/j.soc.2023.12.004
N/A
0DataRank · unranked
14 citations

Shumei Kato, Razelle Kurzrock, Yu Fujiwara

The Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiovascular Outcomes in Patients With Cancer: A Systematic Review and Meta-Analysis

The American Journal of Cardiology(2024)10.1016/j.amjcard.2024.01.032
N/A
0DataRank · unranked
9 citations

Usama Qamar, Yu Fujiwara, Avirup Guha, Abdul Rafeh Naqash, Eric H. Yang +4 more

Tumor mutational burden, PD-1, negative Wnt/β-catenin regulators, and positive MHC class II antigen presentation regulators as predictors of longer survival after immune checkpoint inhibitors across cancers: A comprehensive analysis of 400 immunity biomarkers.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.2625
N/A
0DataRank · unranked
0 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary Nesline +6 more